For each GBM sample, +1 is applied when the expression of αKG, FTO, and METTL3 is predicted to increase the N6-adenosine methylation, i.e., when the αKG and FTO expressions are lower or equal to the median value of our cohort and when METTL3 expression is higher than the median value of our cohort; −1 is applied when the expression of αKG, FTO, and METTL3 is predicted to decrease the N6-adenosine demethylation, i.e., when the αKG and FTO expressions are higher than the median value of our cohort and when METTL3 expression is lower or equal to the median value of our cohort. Here, METTL3 is linked to glioblastoma.